期刊
CANCER CELL
卷 33, 期 5, 页码 853-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2018.04.001
关键词
-
资金
- Bristol-Myers Squibb
- Bristol-Myers Squibb (Princeton, NJ)
- ONO Pharmaceutical Company, Ltd. (Osaka, Japan)
- NATIONAL CANCER INSTITUTE [P30CA008748, P30CA076292] Funding Source: NIH RePORTER
Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032. Patients received nivolumab (3 mg/kg every 2 weeks) or nivolumab plus ipilimumab (1 mg/kg plus 3 mg/kg every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks). Efficacy of nivolumab +/- ipilimumab was enhanced in patients with high tumor mutational burden. Nivolumab plus ipilimumab appeared to provide a greater clinical benefit than nivolumab monotherapy in the high tumor mutational burden tertile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据